Giampietro Gregis
Overview
Explore the profile of Giampietro Gregis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torti C, Raffetti E, Donato F, Castelli F, Maggiolo F, Angarano G, et al.
Int J Epidemiol
. 2015 Oct;
46(2):e12.
PMID: 26445966
No abstract available.
2.
Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, et al.
J Acquir Immune Defic Syndr
. 2012 Apr;
60(5):473-82.
PMID: 22481602
Background: Low-level viremia (LLV) is measurable, with enhanced assays, in many subjects with HIV RNA levels <50 copies per milliliter. The clinical consequences of LLV are unknown. Methods: In a...
3.
Leone S, Gregis G, Noviello S, Esposito S
J Antimicrob Chemother
. 2011 Aug;
66(11):2682-3.
PMID: 21810835
No abstract available.
4.
Maggiolo F, Airoldi M, Callegaro A, Martinelli C, Dolara A, Bini T, et al.
AIDS
. 2008 Dec;
23(7):799-807.
PMID: 19114869
Objective: To compare continuous HAART with a CD4 cell-driven scheduled treatment interruption (STI) strategy. Methods: LOng Term Treatment Interruption study is a randomized, controlled, prospective trial. Patients with CD4 cell...
5.
Maggiolo F, Airoldi M, Callegaro A, Ripamonti D, Gregis G, Quinzan G, et al.
J Int Assoc Physicians AIDS Care (Chic)
. 2007 Jun;
6(2):87-93.
PMID: 17537998
The authors assessed the predictive capacity of 3 rule-based algorithms (Bergamo, Stanford University, Rega Institute) for HIV genotypic interpretation. A total of 1132 postgenotypic regimens in 533 patients were considered....
6.
Maggiolo F, Arici C, Airoldi M, Ripamonti D, Quinzan G, Gregis G, et al.
J Antimicrob Chemother
. 2007 Jan;
59(3):569-72.
PMID: 17255141
Objectives: To evaluate the frequency of and predictive factors for nevirapine-based highly active antiretroviral therapy (HAART) discontinuation. Methods: All patients receiving nevirapine as a component of HAART at our centre...
7.
Maggiolo F, Ripamonti D, Callegaro A, Gregis G, Quinzan G, Suter F
HIV Clin Trials
. 2005 Mar;
6(1):1-4.
PMID: 15765306
A randomized controlled study exploring an induction-maintenance strategy was performed with a quadruple-drug regimen: zidovudine/lamivudine/abacavir/nevirapine. The study was prematurely interrupted due to the high proportion of adverse events. The median...
8.
Matteelli A, Saleri N, Bisoffi Z, Gregis G, Gaiera G, Visona R, et al.
Antimicrob Agents Chemother
. 2005 Jan;
49(2):663-7.
PMID: 15673749
We conducted a multicenter, randomized, open-label trial to compare mefloquine with a 3-day quinine plus sulphalene-pyrimethamine (SP) regimen for the treatment of imported uncomplicated malaria acquired in Africa. The end...
9.
Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quinzan G, Arici C, et al.
Clin Infect Dis
. 2004 Dec;
40(1):158-63.
PMID: 15614706
Background: This prospective study verified the effect of adherence on the risk of virologic failure. Methods: At enrollment in the study, a total of 543 patients who were following a...
10.
Maggiolo F, Ripamonti D, Ravasio L, Gregis G, Quinzan G, Callegaro A, et al.
Clin Infect Dis
. 2003 Jun;
37(1):41-9.
PMID: 12830407
In a prospective, open-label, 104-week study, patients who were infected with human immunodeficiency virus type 1 (virus load, <50 copies/mL) and who were receiving protease inhibitor-based therapy were randomly assigned...